Achieving Low Disease Activity in Lupus Nephritis: A Step Forward in Management
Achieving a low disease activity state in lupus nephritis significantly reduces relapse risk and helps preserve kidney function, offering hope for better long-term management of the condition.
Recent research highlights that achieving a low disease activity state (LLDAS) in patients with lupus nephritis is possible and is associated with improved outcomes. A study published online in Arthritis Care & Research on July 20, 2025, demonstrates that both complete renal response (CRR)/partial renal response (PRR) and LLDAS are linked to higher relapse-free survival rates. The study involved 245 adult lupus nephritis patients, with findings revealing that 40% achieved CRR, 10% achieved PRR, and 49% attained LLDAS after 12 months.
The research, led by Chak Kwan Cheung from The University of Hong Kong, shows that attaining these treatment targets independently reduces the risk of disease relapse and helps preserve kidney function long-term. Specifically, achieving CRR/PRR and LLDAS was associated with hazard ratios of 0.31 and 0.38, respectively, indicating a significant decrease in relapse risk.
Importantly, the study emphasizes that LLDAS can be an attainable and effective treatment goal in lupus nephritis management. The authors suggest that aiming for LLDAS, either alone or alongside CRR/PRR, leads to better patient outcomes, including a lower chance of disease relapse and better renal function preservation.
This evidence encourages clinicians to incorporate LLDAS into treatment protocols, helping improve long-term quality of life for patients with lupus nephritis. For further details, see the full study in Arthritis Care & Research (DOI: 10.1002/acr.25611).
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Prebiotics as a Potential Strategy to Boost Brain GABA and Prevent Neurological Disorders
New research reveals that prebiotics may enhance brain GABA levels by modulating gut microbiota, offering promising avenues for treating neurological disorders like depression and epilepsy.
FDA Urges Implementation of Child-Resistant Packaging on Nicotine Pouches to Protect Children
The FDA urges nicotine pouch manufacturers to implement child-resistant packaging to prevent accidental poisoning among children, amid rising exposure cases and risks associated with colorful, attractive designs.
New Evolutionary Model Highlights the Importance of Dose Timing in Antibiotic Resistance Management
A groundbreaking study introduces a new evolutionary model showing that the timing of antibiotic doses, especially early doses, is crucial in preventing bacterial resistance. Accurate dosing schedules can improve treatment outcomes and curb the rise of superbugs.